MedTech Valuation Multiples and Comparable Analysis

Introduction

MedTech valuation sits between pharmaceuticals and healthcare services in terms of multiple ranges, but the dispersion within MedTech is among the widest in healthcare. A large-cap diversified device company might trade at 13-15x forward EBITDA while a high-growth pure-play in structural heart or surgical robotics trades at 20-30x. Understanding what drives this dispersion is critical for healthcare bankers structuring M&A transactions, building fairness opinions, and advising on capital markets activity.

Rule of 40 in MedTech

Borrowed from SaaS, the Rule of 40 states that a company's revenue growth rate plus its EBITDA margin should exceed 40%. Applied to MedTech: a company growing revenue 15% with a 28% EBITDA margin scores 43 (above the threshold). A company growing 5% with a 22% margin scores 27 (below). MedTech companies exceeding the Rule of 40 consistently trade at premium multiples, while those below it trade at discounts. This framework is increasingly used by MedTech investors because it captures the growth-profitability tradeoff that drives valuation: rapid growth is valuable even at lower margins, and high margins are valuable even at moderate growth.

Organic Revenue Growth

The single strongest predictor of MedTech valuation multiples is the organic revenue growth rate. For every percentage point of organic growth above the MedTech industry average (~5-6%), a company typically earns 1-2 additional turns of EV/EBITDA. This relationship is non-linear: the premium accelerates for companies growing above 10%, which partially explains why Edwards Lifesciences (high-teens growth in TAVR) trades at 3-4x the multiple of Medtronic (low-single-digit organic growth).

Revenue Quality and Recurring Mix

As discussed in The MedTech Business Model, companies with higher recurring revenue (consumables + services as a percentage of total revenue) command premium multiples because of greater revenue visibility and lower cyclicality. The market rewards the razor/blade model with 3-5 additional EBITDA turns relative to capital equipment-heavy peers.

Margin Profile

EBITDA margins in MedTech range from the high teens (capital equipment-heavy, direct sales force) to the mid-30s (high-margin consumables, efficient operations). Higher-margin companies trade at premium multiples, though the market distinguishes between sustainably high margins (driven by competitive moats and product differentiation) and temporarily high margins (driven by pricing that may face competitive erosion).

Competitive Moat

Devices with PMA approval (regulatory moat), proprietary platforms with high switching costs (installed base moat), or physician preference driven by surgeon training (behavioral moat) all command premium valuations. Devices competing in commoditized 510(k) categories with 4-5+ competitors trade at lower multiples.

Segmentation Criteria

The most useful MedTech peer groups are constructed using three dimensions:

Device category alignment. Cardiovascular, orthopedics, surgical/general, diagnostics, neuromodulation, and diabetes each have distinct characteristics. Cross-category comparisons are appropriate only for diversified companies of similar portfolio mix.

Growth profile matching. Group companies by organic growth rate (sub-3%, 3-6%, 6-10%, 10%+) to ensure the comps reflect similar investor expectations. A 15%-growth company among 4%-growth peers will distort averages.

Business model type. Separate razor/blade companies (high recurring revenue, installed base economics) from single-use device companies (implants, disposables without installed base lock-in) and from capital equipment companies (imaging, large systems).

MedTech M&A transaction multiples provide a complementary valuation reference, reflecting strategic premiums and control value above trading multiples. Recent benchmarks:

The next article covers MedTech KPIs and financial profile, the specific metrics analysts track for device companies.